User login
Key clinical point: An automated image cytometry system called CytoPAN provides rapid cancer profiling and requires “scant” cellular specimens, according to researchers.
Major finding: In preclinical experiments, CytoPAN detected cancer in 1 hour using as few as 50 cells. In a patient cohort, CytoPAN detected breast cancer with 100% accuracy.
Study details: Preclinical research and a prospective study of 68 breast cancer patients.
Disclosures: The authors received funding from the National Institutes of Health, the MGH Scholar Fund, and Robert Wood Johnson Foundation. Some authors disclosed relationships with Akili, Accure Health, ModeRNA, Tarveda, Lumicell, and Noul.
Citation: Min J et al. Sci Transl Med. 2020 Aug 5. doi: 10.1126/scitranslmed.aaz9746.
Key clinical point: An automated image cytometry system called CytoPAN provides rapid cancer profiling and requires “scant” cellular specimens, according to researchers.
Major finding: In preclinical experiments, CytoPAN detected cancer in 1 hour using as few as 50 cells. In a patient cohort, CytoPAN detected breast cancer with 100% accuracy.
Study details: Preclinical research and a prospective study of 68 breast cancer patients.
Disclosures: The authors received funding from the National Institutes of Health, the MGH Scholar Fund, and Robert Wood Johnson Foundation. Some authors disclosed relationships with Akili, Accure Health, ModeRNA, Tarveda, Lumicell, and Noul.
Citation: Min J et al. Sci Transl Med. 2020 Aug 5. doi: 10.1126/scitranslmed.aaz9746.
Key clinical point: An automated image cytometry system called CytoPAN provides rapid cancer profiling and requires “scant” cellular specimens, according to researchers.
Major finding: In preclinical experiments, CytoPAN detected cancer in 1 hour using as few as 50 cells. In a patient cohort, CytoPAN detected breast cancer with 100% accuracy.
Study details: Preclinical research and a prospective study of 68 breast cancer patients.
Disclosures: The authors received funding from the National Institutes of Health, the MGH Scholar Fund, and Robert Wood Johnson Foundation. Some authors disclosed relationships with Akili, Accure Health, ModeRNA, Tarveda, Lumicell, and Noul.
Citation: Min J et al. Sci Transl Med. 2020 Aug 5. doi: 10.1126/scitranslmed.aaz9746.